2-hexyl-4-Pentynoic Acid
(Synonyms: 2-正己基-4-戊炔酸,(±)-2-Hexyl-4-pentynoic acid) 目录号 : GC11249
An HDAC inhibitor
Cas No.:96017-59-3
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
2-hexyl-4-Pentynoic Acid is a potent and robust inhibitor of HDAC with IC50 value of 13 μM [1].
Histone deacetylases (HDACs) are a class of enzymes that remove acetyl groups from ε-N-acetyl lysines on histones, allowing the histones to wrap the DNA more tightly. DNA expression is regulated by de-acetylation and acetylation.
2-hexyl-4-Pentynoic Acid, a valproic acid (VPA) derivatives, is a potent and robust HDACs inhibitor. In cerebellar granule cells, 2-hexyl-4-Pentynoic Acid (5 μM) significantly and dose-dependently increased acetylated histone H3 (Ac-H3) levels, and at 50-100 μM led to a maximal increase of 600-700%, compared with only a 200% increase by VPA at 100 μM. 2-hexyl-4-Pentynoic Acid also completely blocked glutamate-induced cell death at 50-100 μM. Also, 2-hexyl-4-Pentynoic Acid restored glutamate-induced neuronal loss. At 50 μM, 2-hexyl-4-Pentynoic Acid effectively increased HSP70-1a and HSP70-1b mRNA levels through HDAC inhibition [1].
Reference:
[1]. Leng Y, Marinova Z, Reis-Fernandes MA, et al. Potent neuroprotective effects of novel structural derivatives of valproic acid: potential roles of HDAC inhibition and HSP70 induction. Neurosci Lett, 2010, 476(3): 127-132.
| Cas No. | 96017-59-3 | SDF | |
| 别名 | 2-正己基-4-戊炔酸,(±)-2-Hexyl-4-pentynoic acid | ||
| 化学名 | 2-(prop-2-yn-1-yl)octanoic acid | ||
| Canonical SMILES | CCCCCCC(C(O)=O)CC#C | ||
| 分子式 | C11H18O2 | 分子量 | 182.26 |
| 溶解度 | ≥ 15.45mg/mL in DMSO | 储存条件 | Store at -20°C |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 5.4867 mL | 27.4333 mL | 54.8667 mL |
| 5 mM | 1.0973 mL | 5.4867 mL | 10.9733 mL |
| 10 mM | 0.5487 mL | 2.7433 mL | 5.4867 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet